Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2022.2152323
Abstract: ABSTRACT Introduction In solid tumor immunotherapy, less than 20% of patients respond to anti-programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) agents. The role of transforming growth factor β (TGFβ) in diverse… read more here.
Keywords: immunotherapy; blockade tgf; blockade; solid tumors ... See more keywords
Blockade of only TGF-β 1 and 2 is sufficient to enhance the efficacy of vaccine and PD-1 checkpoint blockade immunotherapy
Sign Up to like & getrecommendations! Published in 2017 at "OncoImmunology"
DOI: 10.1080/2162402x.2017.1308616
Abstract: ABSTRACT Checkpoint inhibition has established immunotherapy as a major modality of cancer treatment. However, the success of cancer immunotherapy is still limited as immune regulation of tumor immunity is very complicated and mechanisms involved may… read more here.
Keywords: tumor immunity; blockade; blockade tgf; vaccine ... See more keywords